BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31050692)

  • 1. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
    Barra F; Scala C; Ferrero S
    Drugs Today (Barc); 2019 Apr; 55(4):237-246. PubMed ID: 31050692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
    Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
    Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of elagolix for the treatment of endometriosis.
    Melis GB; Neri M; Corda V; Malune ME; Piras B; Pirarba S; Guerriero S; OrrĂ¹ M; D'Alterio MN; Angioni S; Paoletti AM
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):581-8. PubMed ID: 27021205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elagolix for endometriosis: all that glitters is not gold.
    Vercellini P; ViganĂ² P; Barbara G; Buggio L; Somigliana E;
    Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
    Ezzati M; Carr BR
    Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of elagolix in the treatment of endometriosis.
    Perricos A; Wenzl R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elagolix: First Global Approval.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
    Fantasia HC
    Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
    Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
    J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
    Taylor HS; Dun EC; Chwalisz K
    Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Emerging Therapeutics for the Management of Endometriosis.
    Ferrero S; Barra F; Leone Roberti Maggiore U
    Drugs; 2018 Jul; 78(10):995-1012. PubMed ID: 29946962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
    Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
    N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.
    Barra F; Grandi G; Tantari M; Scala C; Facchinetti F; Ferrero S
    Expert Opin Biol Ther; 2019 Apr; 19(4):343-360. PubMed ID: 30763525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
    Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
    [No Abstract]   [Full Text] [Related]  

  • 16. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
    Pokrzywinski RM; Soliman AM; Chen J; Snabes MC; Coyne KS; Surrey ES; Taylor HS
    Am J Obstet Gynecol; 2020 Jun; 222(6):592.e1-592.e10. PubMed ID: 31759891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
    Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
    Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
    Diamond MP; Carr B; Dmowski WP; Koltun W; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
    Reprod Sci; 2014 Mar; 21(3):363-71. PubMed ID: 23885105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational drugs for the treatment of endometriosis, an update on recent developments.
    Barra F; Scala C; Mais V; Guerriero S; Ferrero S
    Expert Opin Investig Drugs; 2018 May; 27(5):445-458. PubMed ID: 29708812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
    Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
    Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.